New triple attack on advanced cancers enters human testing
NCT ID NCT07285395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and tumor response. The goal is to find the best dose of AT1019 for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?